By Ruchika Sharma
Hyderabad: Natco Pharma has announced that Dr Muddasaani Pulla Reddy, Executive Vice President – R & D and CH Srinivas, Senior Vice President – Demand & Supply have superannuated from the Company.In addition, R. Sridhar Reddy – Senior Vice President – GCQA has resigned from the Company. Prior to Natco, Sridhar served at Life Pharma FZE Dubai, Aurobindo Pharma, Medley Pharmaceuticals Ltd, Gland Pharma and Strides Arcolab.Earlier in April, Natco Pharma also announced the superannuation of two key executives: Dr. Ramesh Dandala, Executive Vice President – Technology Transfer, Intellectual Property Rights & Regulatory Affairs (API), and Tummala Venkata Rao, Vice President – Production.Read also: Natco Pharma announces key leadership appointments across quality, operations, regulatory, distribution teamsNATCO Pharma Limited, headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharma ingredients and crop protection products. Natco is a R&D oriented, and a science driven, Oncology company in the targeted therapies of domestic market and focuses on limited competition molecule in the US. The Company’s manufacturing facilities are approved by several leading regulatory authorities like US FDA, Brazil ANVISA, Health Canada, WHO and others catering to 50+ global markets.Read also: Natco Pharma appoints Yarramshetty Krishna Rao as Senior Vice President – Operations at Mekaguda